Disclosures: Sadatsugu Sakane: Nothing to Disclose, Hiroaki Fuji: Nothing to Disclose, Animesh Singh: Nothing to Disclose, Hyun Young Kim: Nothing to Disclose, Mojgan Hosseini: Nothing to Disclose, Yusuke Kimura: Nothing to Disclose, Raquel Weber: Nothing to Disclose, Wonseok Lee: Nothing to Disclose, Kanani Hokutan: Nothing to Disclose, Souradipta Ganguly: Nothing to Disclose, Karin Diggle: Nothing to Disclose, Xiao Liu: Nothing to Disclose, Debanjan Dhar: Nothing to Disclose, Linda Burkly Burkly: Editas Medicine: Employee, David Brenner: Nothing to Disclose, Tatiana Kisseleva: Nothing to Disclose 1990 PRECLINICAL PROOF OF CONCEPT OF SAFETY AND EFFICACY FOR RTX001, A NOVEL AUTOLOGOUS MACROPHAGE CELL THERAPY PRODUCT FOR END-STAGE LIVER DISEASE Moony Su 1 Olivia Matthews 1 Mark Cant 1 Anna Hoy 1 Niya Aleksieva 1 Rachel Lopera 1 Philip Starkey Lewis 1 Alejandro Armesilla-Diaz 1 Keith Sutton 1 Kayleigh Thirlwell 1 Lara Campana 1 , 1 Resolution Therapeutics Background: Patients with end-stage liver disease (ESLD) have extensive fibrosis and inflammation, which cause loss of organ function, resulting in decompensation events and limited life expectancy

K.KrederK
doi: 10.1016/j.jss.2023.05.006 51 LiJLuKSunFTanSZhangXShengWet al
RZTLICHE BERATUNG & FUNKTIONELLE MEDIZIN Wir verstehen funktionelle Medizin als ursachenorientierten, patientenzentrierten Ansatz
If you are already using one, it is natural to wonder if adding the other will help or if they will compete for absorption in your system
10.2527/2005.833634x 126